Allarity Therapeutics reported financial results for the second quarter ended June 30, 2026, ending with $26.9 million in cash and restricted cash. The company completed a Phase 3-ready manufacturing campaign for its drug candidate stenoparib in July 2026 and obtained CLIA certification for its in-house laboratory to support clinical trials. Additionally, the USPTO granted a key U.S. patent protecting the exclusivity of stenoparib when used with its DRP companion diagnostic into April 2042. R&D expenses were $1.3 million and G&A expenses were $1.3 million for the quarter. Allarity Therapeutics is a clinical-stage biopharmaceutical company developing personalized cancer treatments using stenoparib and its proprietary drug response predictor technology.
